tiprankstipranks
Pure Bioscience (PURE)
OTHER OTC:PURE
US Market
Want to see PURE full AI Analyst Report?

Pure Bioscience (PURE) Price & Analysis

46 Followers

PURE Stock Chart & Stats

$0.05
<$0.01(1.96%)
At close: 4:00 PM EST
$0.05
<$0.01(1.96%)

Bulls Say, Bears Say

Bulls Say
Proprietary TechnologyPure’s proprietary SDC silver-based antimicrobial technology represents a durable product differentiation and IP foundation. In markets where sanitation is structural (food, institutional), a unique active ingredient can support recurring product demand, licensing, and long-term competitive positioning.
Revenue RecoverySustained top-line growth (TTM +~62%) indicates improving market adoption and distribution traction after prior declines. If maintained, rising revenue can enable scale benefits, improve gross absorption of fixed costs, and provide a runway to pursue margin improvement and commercial expansion.
Insider-backed FinancingThe $1.0M private placement with material insider participation strengthens near-term liquidity and signals management alignment. This financing provides incremental runway for R&D, working capital and commercialization, reducing immediate solvency pressure while management executes on growth initiatives.
Bears Say
Persistent LossesConsistent operating and net losses erode resilience: persistent unprofitability limits internally generated capital, constrains reinvestment capacity, and forces reliance on external funding. Over months, continued losses increase refinancing and execution risk if growth doesn’t translate to profitability.
Negative EquityAccumulated losses produced negative stockholders’ equity, weakening the capital structure. Negative equity distorts leverage metrics, limits borrowing capacity, and elevates insolvency risk over time, making the company vulnerable to adverse operating shocks or tighter financing conditions.
Consistent Cash BurnPersistent negative operating and free cash flow (~-$1.8M TTM) indicate the core business does not self-fund. Ongoing cash burn forces repeated external financing, creates dilution/refinancing risk, and reduces flexibility to invest in sales or product development if capital access tightens.

Pure Bioscience News

PURE FAQ

What was Pure Bioscience’s price range in the past 12 months?
Pure Bioscience lowest stock price was $0.04 and its highest was $0.14 in the past 12 months.
    What is Pure Bioscience’s market cap?
    Pure Bioscience’s market cap is $8.44M.
      When is Pure Bioscience’s upcoming earnings report date?
      Pure Bioscience’s upcoming earnings report date is Nov 03, 2026 which is in 103 days.
        How were Pure Bioscience’s earnings last quarter?
        Pure Bioscience released its earnings results on Jun 15, 2026. The company reported -$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
          Is Pure Bioscience overvalued?
          According to Wall Street analysts Pure Bioscience’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Pure Bioscience pay dividends?
            Pure Bioscience does not currently pay dividends.
            What is Pure Bioscience’s EPS estimate?
            Pure Bioscience’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Pure Bioscience have?
            Pure Bioscience has 130,017,560 shares outstanding.
              What happened to Pure Bioscience’s price movement after its last earnings report?
              Pure Bioscience reported an EPS of -$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.857%.
                Which hedge fund is a major shareholder of Pure Bioscience?
                Currently, no hedge funds are holding shares in PURE
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Pure Bioscience

                  PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a ready-to-use hard surface disinfectant and food contact surface sanitizer and disinfectant; PURE Control, eliminates pathogens in produce, such as salmonella, e. coli, and listeria; PURE Multi-Purpose Hi-Foam Floor Cleaner Concentrate, a cleaning product for stainless steel, floors, walls, and painted areas; PURE Multi-Purpose Floor Cleaner, for sanitation in food processing plants, commercial kitchens, healthcare facilities, schools, and hospitality settings; and SILVERION, a SDC-based antimicrobial formulation for use as a raw material ingredient in the manufacturing of personal care products. The company serves food processing, food service and hospitality, healthcare, facility care, transportation, and personal care industries. It sells its products through end-use customers and third-party distributors. The company was incorporated in 1992 and is based in El Cajon, California.

                  Pure Bioscience (PURE) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Mannatech
                  United-Guardian
                  Tantech Holdings
                  Grove Collaborative Holdings
                  Yoshitsu Co. Ltd. Sponsored ADR

                  Ownership Overview

                  0.62%99.38%
                  Insiders
                  Mutual Funds
                  0.62% Other Institutional Investors
                  99.38% Public Companies and
                  Individual Investors
                  Popular Stocks